Table 2:

Maximum reactogenicity within 7 days of vaccination

	All ZPIV (N=30)	Placebo (N=6)
Local symptoms
Any local symptom	26 (87%)	3 (50%)
Mild	23 (77%)	3 (50%)
Moderate	3 (10%)	0
Erythema	26 (87%)	3 (50%)
Mild	23 (77%)	3 (50%
Moderate	3 (10%)	0
Induration (severity)	4 (13%)	1 (17%)
Mild	4 (13%)	1 (17%)
Moderate	0	0
Induration (size)	4 (13%)	1 (17%)
Mild	4 (13%)	1 (17%)
Moderate	0	0
Pruritus	1 (3%)	0
Mild	1 (3%)	0
Moderate	0	0
Pain	24 (80%)	2 (33%)
Mild	21 (70%)	2 (33%)
Moderate	3 (10%)	0
Systemic symptoms
Any systemic symptom	24 (80%)	4 (67%)
Mild	18 (60%)	3 (50%)
Moderate	6 (20%)	1 (17%)
Abdominal Pain	3 (10%)	1 (17%)
Mild	2 (7%)	0
Moderate	1 (3%)	1 (17%)
Arthralgia	2 (7%)	0
Mild	2 (7%)	0
Moderate	0	0
Diarrhea	5 (17%)	0
Mild	5 (17%)	0
Moderate	0	0
Fatigue	16 (53%)	1 (17%)
Mild	12 (40%)	1 (17%)
Moderate	4 (13%)	0
Feverishness	4 (13%)	1 (17%)
Mild	3 (10%)	1 (17%)
Moderate	1 (3%)	0
Headache	14 (46%)	2 (33%)
Mild	10 (33%)	2 (33%)
Moderate	4 (13%)	0
Malaise	10 (34%)	1 (17%)
Mild	8 (27%)	1 (17%)
Moderate	2 (7%)	0
Myalgia	13 (44%)	1 (17%)
Mild	11 (37%)	1 (17%)
Moderate	2 (7%)	0
Nausea	7 (23%)	1 (17%)
Mild	6 (20%)	1 (17%)
Moderate	1 (3%)	0
Rash	1 (3%)	0
Mild	0	0
Moderate	1 (3%)	0
Fever	1 (3%)	0
Mild	0	0
Moderate	1 (3%)	0
Vomiting	2 (7%)	0
Mild	2 (7%)	0
Moderate	0	0

N = Number of participants in the Safety Population who received the specified dose. ZPIV=Alum-adjuvanted Zika purified inactivated vaccine.